Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease
| Autor: | D. Fleischhacker, Hisham K. Tamimi, Laurel W. Rice, Marit Ek, Benjamin E. Greer, Arlan F. Fuller, Ricardo Sainz de la Cuesta, Joanna M. Cain, Barbara A. Goff, Howard G. Muntz, Najmosama Nikrui |
|---|---|
| Rok vydání: | 1996 |
| Předmět: |
Adult
medicine.medical_specialty Endometriosis Gastroenterology Ovarian Clear Cell Adenocarcinoma Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Carcinoma Humans Clear-cell ovarian carcinoma Aged Neoplasm Staging Aged 80 and over Ovarian Neoplasms business.industry Obstetrics and Gynecology Middle Aged medicine.disease Prognosis Survival Analysis Surgery Oncology Clear cell carcinoma Female Cisplatin Ovarian cancer business Clear cell Progressive disease Adenocarcinoma Clear Cell |
| Zdroj: | Gynecologic oncology. 60(3) |
| ISSN: | 0090-8258 |
| Popis: | Between 1982 and 1992, 24 women with Stage III clear cell ovarian cancer were identified from the tumor registry. Thirty-four women with Stage III papillary serous tumors treated between 1987 and 1989 were used as a comparison. All patients underwent cytoreductive surgery followed by conventional platinum-based chemotherapy. In the women with clear cell histology, nine (37.5%) had endometriosis in the surgical specimen compared with one (3%) in the papillary serous group (P = 0.002). Ten women (42%) with clear cell histology experienced a thromboembolic event during the course of treatment, compared to six (18%) in the papillary serous group (P = 0.05). In the group with clear cell histology, overall, 70% of women had progressive disease. Fifty-two percent experienced clinical progression while receiving platinum-based chemotherapy. In addition, four patients were found to have progressive disease at second-look laparotomy. Only two patients had a pathologic complete response. In the group with papillary serous histology, 29% overall had progressive disease while on chemotherapy (P = 0.005). The median survival for the women with clear cell histology was 12 months compared to 22 months for those with papillary serous (P = 0.02). For women with clear cell histology, univariate analysis was used to evaluate prognostic factors. Age less than 50 was a poor prognostic factor (P = 0.045). The presence of endometriosis, thromboembolic event, or optimal cytoreduction were not prognostic factors (P = 0.67, P = 0.34, P = 0.39). Patients with advanced clear cell ovarian cancer have a poor response to conventional platinum-based chemotherapy and overall prognosis is poor. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect